Agne Paner to Multiple Myeloma
This is a "connection" page, showing publications Agne Paner has written about Multiple Myeloma.
Connection Strength
2.529
-
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020 05; 41:100643.
Score: 0.708
-
Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. Expert Rev Hematol. 2018 12; 11(12):957-973.
Score: 0.662
-
Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423.
Score: 0.213
-
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. Br J Haematol. 2022 02; 196(3):639-648.
Score: 0.202
-
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767.
Score: 0.190
-
Melflufen for relapsed and refractory multiple myeloma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1069-1078.
Score: 0.188
-
Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020 Aug; 35(4):307-315.
Score: 0.184
-
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453.
Score: 0.181